Introduction {#Sec1}
============

Congenital neutropenia (CN) is a group of rare and inherited hematological disorders characterized by chronic profound neutropenia caused by impaired differentiation of neutrophilic granulocytes. Often diagnosed early in life, CN is defined as recurrent, life-threatening bacterial infections (e.g., skin infections, otitis, gingivitis, abscesses and sepsis) \[[@CR1]\]. The elastase, neutrophil-expressed (*ELANE*) gene encodes neutrophil elastase, and is responsible for *ELANE* neutropenia, which is probably the most frequent and one of the most severe CN forms, based on its infection rate \[[@CR2]\]. Two distinct *ELANE*-related CN phenotypes have been described: cyclic neutropenia (CyN), in which neutrophil counts classically oscillate with 21-day periodicity, and severe congenital neutropenia (SCN), with persistently low blood neutrophil counts \[[@CR3], [@CR4]\]. The standard-of-care for *ELANE*-neutropenia patients consists of granulocyte-colony--stimulating factor (GCSF) administration, which increases the numbers of circulating neutrophils, thereby lowering infection-related mortality. Hematopoietic stem-cell transplantation (HSCT) is indicated for the rare patients with GCSF-refractory disease (i.e., no absolute neutrophil count (ANC) increase at ≥50 µg/kg/day) or those with myelodysplastic syndrome (MDS) \[[@CR5]--[@CR7]\].

Patients with *ELANE*-related CN are at risk of developing MDS--acute leukemia (MDS--AL). In 2005, our team showed \[[@CR8]\] that the CN leukemia risk depends on two major features, the genetic defect and GCSF use, with the latter controlling the patients' infection rates. The relationship between high-dose GCSF exposure and leukemic transformation was confirmed in 2006 by the International Severe Chronic Neutropenia Registry (ISCNR), in which the USA, Canada, UK, the Netherlands, and Germany participate \[[@CR9]\]. Based on those results, guidelines were issued in France recommending HSCT for patients receiving high-dose GCSF, while the French Severe Chronic Neutropenia Registry has continued to collect data prospectively. This practice represents an extension of the validated indication of HSCT for CN.

This study was undertaken to analyze the effect of this policy on patients with the *ELANE*-gene mutation, as they are currently one of the most heavily GCSF-treated. In addition, even though HSCT has been proposed for CN since 1980 \[[@CR10]\], it has been reported in only 11 patients with known *ELANE* status thus far \[[@CR11]--[@CR18]\]. Therefore, a comprehensive review of these cases appeared useful concerning HSCT indication and its impact.

Patients and methods {#Sec2}
====================

Registry organization and data monitoring {#Sec3}
-----------------------------------------

The patients included in this study were all entered in the French Severe Chronic Neutropenia Registry (FSCNR). First created in 1993, with prospective enrollment of all CN types \[[@CR1]\], the FSCNR was certified as a national registry by health authorities in 2008, and its case completeness was ascertained by verification through multiple sources. The database was approved by the French computer watchdog commission (CNIL certificate no. 97.075). Thirty-five French pediatric hematology--oncology units and \~50 adult hematology units participate in the FSCNR. A clinical research associate assured accurate data monitoring, based on annual on-site reviews of medical charts. The following parameters are currently recorded: sex, age at diagnosis, severe bacterial or fungal infections (septicemia, cellulitis, pneumonia, osteitis and liver abscess), complete blood cell counts, differential bone-marrow cell counts (smear method) and all information on HSCTs. Each patient had to provide written informed consent to be entered in the FSCNR. Several reports on the FSCNR are available elsewhere \[[@CR2], [@CR8], [@CR19]--[@CR24]\].

Study design {#Sec4}
------------

This before--after study compared patients divided into two groups according to follow-up period: "before 2005", for those born before 2005 and followed until 31/12/2004, and "after 2005", for those born after 2005 or before 2005 but still being followed after 2005 until the last update (31/05/2019). The main reason to separate these two periods was the HSCT-indication modification at the end of 2004. Since 2005, patients in France receiving a GCSF dose above the 15-μg/kg/day threshold become eligible for HSCT, in addition to patients with validated indications, such as MDS--AL or GCSF refractoriness (typically ≥50 μg/kg/day).

ELANE-neutropenia genetics {#Sec5}
--------------------------

We classified variants according to American College of Medical Genetics and Genomics guidelines \[[@CR25]\]. Only pathogenic (class 5) and probably pathogenic *ELANE*-gene variants (class 4) were included in this study. The patients or their parents gave written informed consent for genetic testing. Standard procedures were used to extract DNA from blood. The *ELANE-*gene coding sequence and exon--intron boundaries were determined either by Sanger sequencing, as described previously \[[@CR2], [@CR3]\], or by targeted sequencing of a gene panel including *ELANE*. Mutations were numbered as recommended by the Human Genome Variation Society (<http://www.hgvs.org/>), using the reference sequence NM_001972.2.

Literature review {#Sec6}
-----------------

To identify all publications related to *ELANE-*associated neutropenia and summarize reported cases, we first screened PubMed using the keywords "ELANE" "ELA2" "Severe congenital neutropenia" "Congenital neutropenia". Then the reference list of each article was checked to identify additional references and avoid duplicates.

Hematological events {#Sec7}
--------------------

AL, either acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), was defined using WHO criteria (i.e., at least 20% blast cells in bone-marrow smears). Because these patients almost always had dystrophic cytological abnormalities, MDS was diagnosed when cytological abnormalities were associated with central anemia or central thrombocytopenia requiring blood transfusion, and when clonal cytogenetic abnormalities were present. Single-strand conformational polymorphism, as previously described \[[@CR26]\], was used to screen for GCSF-receptor mutations, which were confirmed by sequencing. More recently, targeted next-generation sequencing was used.

GCSF exposure {#Sec8}
-------------

To calculate GCSF exposure, we assumed dose equivalence between filgrastim and lenograstim. Because the unit dose and frequency of GCSF injections are individually tailored, each patient's overall treatment was estimated using several parameters calculated for each GCSF therapeutic period during which the dose and frequency of injections were stable: dose delivered per injection (*dd*~*i*~, µg/kg); number of injections (*n*~*i*~); cumulative dose, defined as the total dose received during the relevant period (mg/kg) = *dd*~*i*~ × *n*~*i*~; and duration of the relevant period in days. The total cumulative dose (µg) was calculated as the sum of cumulative doses for each therapeutic period, from day 1 of GCSF to the last day of follow-up. The cumulative duration of GCSF use (in years) was calculated as the sum of all therapeutic periods. For each patient, total GCSF-therapy follow-up (in years) since onset was calculated from the first injection to the last day. The time-averaged dose (µg/kg/day) was calculated by dividing the cumulative dose by the cumulative duration of treatment.

HSCT and engraftment {#Sec9}
--------------------

The conditioning regimen, donor, type of graft and number of cells injected were recorded. Chimerism analysis was performed by means of cytogenetic or polymerase chain reaction (PCR) amplification of microsatellites on peripheral mononuclear blood cells.

Statistical methods {#Sec10}
-------------------

Demographic, clinical, biological and therapeutic data were recorded using an Access database (Microsoft). Stata® version 13 software was used to compute all statistical analyses. The frequencies were calculated by dividing the numbers of events by the person-years observed for before and after periods. This before--after study compared medical intervention (HSCT) and medical complication (MDS--AL) frequencies between before- and after-2005 groups, using the Mantel--Haensel test \[[@CR27], [@CR28]\]. Categorical data were compared with Fisher's exact test and quantitative data with the Mann--Whitney test. All tests were two-tailed, with *P* \< 0.05 defining significance. For survival analyses, the endpoints were death, bone-marrow transplantation and MDS--AL onset. The Kaplan--Meier method was used to estimate the probability of survival. Survival was compared between before and after groups with the log-rank test \[[@CR29]\].

Results {#Sec11}
=======

Cohort description {#Sec12}
------------------

As of 31 March 2019, among the 1032 CN patients enrolled in the FSCNR, 144 carry a heterozygous, pathogenic *ELANE* mutation. Ninety-five (66%) patients were diagnosed with SCN and 49 (34%) with CyN. The cohort comprised 70 males and 74 females. The median age of the entire cohort at diagnosis was 0.24 (range 0--42.9) years. Respective median ages at SCN or CyN diagnosis were 0.19 or 0.8 years (*P* \< 0.002). The cumulative observation times were 1588 person-years for the 89 patients in the before-2005 group and 1327 person-years for those in the after-2005 group (55 born after 2005 and 84 born before 2005 but followed since 2005). Five patients born before 2005 were not followed after 2005 because they developed MDS--AL, died or underwent HSCT. GCSF treatments were individually tailored based on the recurrence of severe infections and GCSF tolerance. For the entire cohort, 112 patients received GCSF, at a mean dose of 9.8 µg/kg/day, and 32 patients were not given GCSF. The mean (range) total doses (µg/kg) were 9837 (0--115 431) for the entire cohort, 12 564 (0--115 431) for SCN patients and 3837 (0--25 038) for those with CyN. For the 112 treated patients, the time-averaged dose (µg/kg/day) was 0.1--4.9 for three (2.7%) patients, 5--9.9 for 47 (42%), 10--14.9 for 26 (23.2%), 15--29.9 for 14 (12.5%) or 30--49.9 for nine (8.0%) and \>50 µg/kg/day for 13 (11.6%). Maximum doses (µg/kg/day) were \< 5 for 32 (22.2%) patients, 5--10 for 38 (26.4%), 10--20 for 32 (22.2%), 20--30 for 26 (18%) or \>30 for 16 (11.1%). Five patients' neutropenias were considered GCSF-refractory (ANC \< 0.2 G/L after receiving ≥50 µg/kg/day).

Six leukemic transformations occurred, including one ALL. None of the patients followed after 2005 developed MDS--AL. For the entire cohort, the cumulative MDS--AL frequencies (SD) were 4.4% (1.9) at 10 years and 5.5% (2.2) at 20 years. Two patients initially diagnosed with MDS developed AL. No CyN patients developed MDS--AL. Diabetes insipidus with pituitary nodules was the first manifestation for two patients. Among the six MDS--AL patients, three had monosomy-7, and one a complex caryotype and 2 have no identified cytogenetic clone. A *CSF3R* mutation was detected at the time of malignant transformation in 2 patients \[[@CR30]\]. The mean GCSF dose before MDS--AL for the six patients was 18.9 μg/kg/day. Median age at AL onset was 10.75 (range 4.2--12.5) years. The two patients who did not undergo HSCT died of leukemia, while, among the four transplanted patients (two for AML, one for ALL and one for MDS); patient \#3 died of HSCT-related complications, despite complete engraftment.

Seven of the 144 cohort patients died. The 20- and 40-year overall survival rates (95% CI) were 95.7% (90--98.2%) and 92.4% (79.1--97.2%), respectively (Fig. [1b](#Fig1){ref-type="fig"}). Five nontransplanted patients died. Before 2005, two deaths were attributed to AL complications without HSCT; another died of sepsis. After 2005, one adult died of sepsis during a chemotherapy regimen for colon cancer and another died of septic shock and renal failure.Fig. 1Kaplan--Meier estimated probabilities of survival with 95% confidence intervals (CI).(**a**) the entire French Severe Chronic Neutropenia Registry cohort of 144 patients, (**b**) the same cohort according to their dates of birth (before 2005 or after 2005) and (**c**) the 16 French *ELANE*-neutropenia cohort patients after hematopoietic stem-cell transplantation (HSCT).

Description of the 16 patients who underwent HSCT {#Sec13}
-------------------------------------------------

Six males and ten females underwent HSCT (Table [1](#Tab1){ref-type="table"}). Median age at transplantation was 4.3 (range 0.6--20.4) years. All 16 underwent preparatory myeloablation: nine were given a combination of busulfan, cyclophosphamide and anti-thymocyte globulin (ATG); six were given fludarabine and busulfan, combined with ATG alone for four, and melphalan and ATG for one, and thiotepa and ATG for one. One patient underwent TAM12 (total body irradiation, cytarabine and melphalan). A *Gly214Arg* mutation was detected in 6/16 (37.5%) HSCT recipients. HSCTs were done in 4/89 before-2005 patients and 12/139 after-2005 patients (Table [2](#Tab2){ref-type="table"}).Table 1Main characteristics of 16 *ELANE*-neutropenia patients who underwent HSCT in France with situation pre HSCT, HSCT conditioning regimen and outcome.Patient numberMutationIndicationHSCT year^a^/at age, yearConditioning regimenGraft; origin-matchingGVHD prophylaxisNucleated cells, *n*/kgHighest GVHD gradeComplicationsPost-HSCT status/follow-up, yearsDNAProtein1c.688delGp.Asp230fsMDS--AML\>2006/0.92Bu--Cy--ATGMUD; 10/10CSA--MTX43IICMVAlive/132c.125C\>Tp.Pro42leuGCSF failure\>2005/9.28Bu--Cy--ATGMUD; 9/10CSA4.27 × 10^8^IIARDS; cerebral abscess; seizureAlive/12.63c.640G\>Ap.Gly214ArgALL\<2005/12.39TAM12UCB; 9/10CSA--MTXUnknownIVSepsisDied/0.74c.158A\>Tp.His53LeuMDS--AML\<2005/4.72Bu--Cy--ATGUCB; 3/6MMF--Pred10.2 × 10^7^INoAlive/16.84c.640G\>Ap.Gly214ArgGCSF failure\<2005/1.58Bu--Cy--ATGT-depleted MUD; 9/10No11.1 × 10^6^ (CD34+)INoAlive/17.76c.640G\>Ap.Gly214ArgMDS--AML\<2005/10.3Bu--Cy--ATGMUD; 10/10CSA--MTX3.45 × 10^8^ICMV, EBVAlive/16.67c.199_207delp.Ser67_Ala69delGCSF failure\>2005/0.83Bu--Cy--ATGSIBCSAUnknownUnknownUnknownAlive/148c.170C\>Tp.Ala57ValHigh-dose GCSF\>2005/0.6Bu--Cy--ATGUCB; 4/6CSA--Pred15.8 × 10^7^NoneNoAlive/10.39c.377C\>Tp.Ser126LeuHigh-dose GCSF\>2005/3.98Flu--Bu--ATGMUD; 10/10CSA49.26 × 10^6^IEBVAlive/6.910c.241_246delp.Arg81_Val82delHigh-dose GCSF\>2005/7.73Flu--Bu--ATGSIBCSA7.66 × 10^8^II (cGVHD)AplasiaAlive/6.411c.193G\>Tp.Val65PheHigh-dose GCSF\>2005/1.28Flu--Bu--ATGMUD; 10/10CSA--MMF19.8 × 10^8^IVTAM, CMV, EBV *Pseudomonas*Died/0.712c.253G\>Ap.Gly85ArgHigh-dose GCSF\>2005/5.12Bu--Cy--ATGMUD; 10/10CSAUnknownIIINoAlive/313c.640G\>Ap.Gly214ArgGCSF failure\>2005/1.52Flu--Bu--ATGUCB; 5/6CSA8.3 × 10^7^NoneLate-onset autoimmunity (ANF + ) and late transplant lossAlive/6.1 (4.2 years after 2nd HSCT)Late rejection despite full engraftment\>2005/ 3.7Flu--Cy--ATGUCB; 5/6CSA0. 83 × 10^8^/kg (0. 24 × 10^6^/kg CD34).IChickenpox14c.640G\>Ap.Gly214ArgGCSF failure\>2005/1.44Flu--BuSIB; 10/10CSA3.77 × 10^8^IINoAlive/5.115c.1A\>Tp.Met1?GCSF failure\>2005/0.73Bu--Th--Flu--ATGMUD; 12/12CSA--MTXUnknownIIEBVAlive/1.716c.640G\>Ap.Gly214ArgGCSF failure\>2005/1.49Bu--Cy--ATGMUDCSAUnknownIIEBVAlive/3.5*HSCT* hematopoietic stem-cell transplantation, *MDS--AML* myelodysplasia--acute myeloid leukemia, *ALL* acute lymphoblastic leukemia, *ANF* antineutrophil factor, *ARDS* acute respiratory distress syndrome, *Bu* busulfan, *Cy* cyclophosphamide, *ATG* anti-thymoglobulin, *Flu* fludarabine, *Th* thiotepa, *MUD* match unrelated donor, *UCB* unrelated cord blood, *SIB* sibling donor, *CSA* cyclosporine, *MTX* methotrexate, *MMF* mycophenolate mofetil, *Pred* prednisone, *cGVHD* chronic graft vs. host disease, *CMV* cytomegalovirus, *EBV* Epstein--Barr virus, *TAM* transplant-associated thrombotic microangiopathy, *TAM12* 12-Gy total body irradiation, cytarabine and melphalan.^a^\<, before or \>, after 2005.Table 2Results by period (Before and after 2005): this before--after study compared medical intervention (HSCT) and medical complication (MDS--AL) frequencies i.e., the number of events per person-years observed, between before- and after-2005 groups, using the Mantel--Haensel test.ParameterBefore 2005After 2005 to 2019*P*Patients at risk, *n*89139^a^Cumulative follow-up, person-years15881327HSCT     *n*412\<0.01     Ratio, person-years2.5 × 10^--3^9 × 10^--3^MDS--AL     *n*60\<0.01     Incidence ratio, person-years3.8 × 10^--3^0Deaths \[cause\], *n*4 \[2 AML, 1 sepsis, 1 HSCT-related\]3 \[1 colon cancer, 1 sepsis, 1 HSCT-related\]Median age at death, year6.836*HSCT* hematopoietic stem-cell transplantation, *MDS--AL* myelodysplasia--acute leukemia, *AML* acute myeloblastic leukemia.^a^55 patients born after 2005; 84 patients born before 2005 and followed until 2019.

All 16 patients achieved complete hematological recovery with full engraftment, and have a normal neutrophil count after HSCT. The median time required for ANCs to reach 0.5 × 10^9^/L was 21 (range 14--77) days; the longest engraftment time refers to an unrelated cord blood (UCB) HSCT in patient \#3. After 9--42 (median 27) days, platelet counts reached 50 × 10^9^/L, without further transfusion. Despite successful engraftment, patient **\#13** developed autoimmunity (antinuclear factor (ANF) titer \> 1/640), lost his graft at 18 months, and was not amenable to immunosuppression. She underwent retransplantation complicated by severe varicella zoster but nonetheless achieved good and stable engraftment and is in good health, without sequelae, 4 years later.

All surviving patients are disease-free and no longer require erythrocyte and platelet transfusions, with normalized ANCs. Complete chimerism was found in all patients.

Median follow-up post-transplantation was 5.7 years and 5-year survival rate was 87.5% \[95% confidence intervals (CI) 58.7--96.7%\] (Fig. [1c](#Fig1){ref-type="fig"}). Two patients died after HSCT: patient \#3 with ALL for which HSCT was indicated, died of sepsis before 2005 and patient \#11 with GCSF-refractory *ELANE* neutropenia, for which HSCT was indicated, died after 2005 of refractory grade-IV GVHD with transplant-associated thrombotic microangiopathy. In addition, six patients had grade-II GVHDs, including one with chronic skin GVHD and persistent livedo.

Comparison of HSCT rates and leukemia rates before vs. after 2005 {#Sec14}
-----------------------------------------------------------------

Comparing before 2005 to after 2005, respectively, median ages were 0.44 years and 0.15 years (nonsignificant difference) at diagnosis, and 6.9 (range, 1.6--12.4) and 0.15 (range, 0.6--9.3) years at transplantation (*P* = 0.06). Median follow-up durations for the before- and after-2005 cohorts were 14.2 (range 0.1--53.4) and 10.4 (range 0.2--14.5) years, respectively (nonsignificant).

Before 2005, HSCT indications were AL for three patients and GCSF refractoriness for one, and GCSF refractoriness for six after-2005 patients: five taking high GCSF doses (15--30 μg/kg/day) and one with MDS (*P* \< 0.03). Neither the mean before- and after-2005 GCSF doses (8.5 vs. 11.6 μg/kg/day, respectively; *P* \< 0.09) nor the maximum doses (respectively, 14.4 vs. 13.6 μg/kg/day; *P* \< 0.15) received by these patients changed significantly with time. Finally, the major change between before and after 2005 was not the dose prescribed initially to treat the patients needing GCSF but the medical decision with regards to the indication of HSCT.

Discussion {#Sec15}
==========

The main finding issued from this population-based study on 144 patients with *ELANE* mutations was that slightly extending the HSCT indication to patients currently taking high-dose GCSF may lessen the risk of leukemia. In our FSCNR experience, leukemia has not been diagnosed in *ELANE*-neutropenia patients since 2005, when we extended the HSCT indication to patients receiving \>15 µg/kg/day of GCSF. Analysis of administered GCSF doses showed no differences between before-2005 and after-2005 mean doses, maximum doses or total doses for transplantation candidates. However, after 2005, the number of HSCTs increased significantly and patients were transplanted at a significantly younger mean age.

*ELANE* neutropenia was identified first in CyN \[[@CR31]\], and then shortly thereafter in chronic neutropenia \[[@CR32]\]. Infections and hematological malignancies are the main life-threatening complications of *ELANE* neutropenia. Long-term use of GCSF to treat CN, which started in 1988, markedly limits the infectious risk, dramatically improving these patients' quality of life. However, it has also raised questions regarding the balance between the natural risk of severe infections and that of iatrogenic leukemic transformation \[[@CR8], [@CR9]\].

Patients carrying an *ELANE* mutation can develop MDS, AML or, more rarely, ALL. The leukemic transformation rate reported in the literature for *ELANE*-neutropenia patients is 15--25% by 20 years of age \[[@CR2], [@CR3], [@CR33]\]. That risk is considered to be stable over time, affecting 25% of the 52 patients in a series from the NIH and US SCN registry \[[@CR33]\]. During the last 20 years, two large case series were reported; one from the ISCNR on 307 patients \[[@CR4]\] and the other from the Hannover genetic laboratory on 213 patients \[[@CR3]\]. Those reports mentioned that 40 HSCTs had been performed but no information was provided about the indications or outcomes. Among the largest series of HSCTs (136 including 39 *ELANE*-neutropenia patients) indicated for SCN \[[@CR6]\], which includes our patients, the HSCT indication was not analyzed, and that series was not population-based. An exhaustive literature review of HSCT for CN identified only 11 cases with a known *ELANE* mutation (Table [3](#Tab3){ref-type="table"}) and sufficient details about transplantation indications and outcomes) \[[@CR11]--[@CR18]\]. All the reported HSCT indications were 'classical' in the literature reviewed: three for MDS--AL and eight for GCSF refractoriness. None of those papers can be used to study the HSCT impact on the risk of developing MDS--AL, because only the numbers of HSCTs during follow-up of all *ELANE*-neutropenia patients are known but not the entire population.Table 3Literature review on HSCT for 11 *ELANE*-neutropenia patients.Ref.Mutation Nucleotide effectMutation protein effectSex/age at diagnosis/age at HSCTHSCT indicationDonor stem- cell source; matchingConditioning regimenGVHD prophylaxisGVHDOutcome/follow-up\[[@CR11]\]NRMutated, not specifiedM/1 month/9 monthsNo response to GCSFMUD CB; 4/6(1) Bu--Cy--ATG (MAC)(1) CSA--MTXNoNo engraftment/42 daysNo engraftment rejectionMUD, CB; 4/6(2) Flu--ATG (RIC) (3) Flu--Mel--Cam (RIC)(2) CSA--MMF (3) CSA--MMFNo aGVHDRejection/5 months Alive/20 months\[[@CR12]\]c.1287A\>GMet(--29)ValM/1 month/--No response to GCSFSIB, BMMACNRNRAlive/47 days\[[@CR13]\]NRp.Leu121HisF/2 weeks/28 years*CSF3R* mutationsSIB, PBSCFlu--Bu--CampFk--RapaNoAlive/60 monthsNRp.His87delM/3 months/14 yearsMDS--AMLMUD, PBSCBu--Cy--Mel--ATGLow CSA--MTXsevere cGVHDAlive/31 monthsNRp.Cys151SerM/1 week/7 yearsGCSF resistance, MDSMUD, CBBu--Cy--Mel--ATGCSA--PredGrade-IV aGVHDDied of aGVHD/40 days\[[@CR14]\]g.2253A\>Cp.Q73PM/16 months/3 yearsNo response to GCSFMUD, BMFlu--Mel--TBI--ATGFk--MTXNRAlive/15 months\[[@CR15]\]NRp.Trp127CysM/1 month/4 yearsNo response to GCSFNRNRNRNoRejection, alive/5 years post-2nd HSCTNRp.Gln208TerM/1 month/31 yearsAMLNRNRNRModerateAlive/7 years\[[@CR16]\]c.401A\>Cp.Gln134Pro,M/12 months/2 yearsNo response to GCSFSIB, BMMel--Flu--TBINRNRAlive\[[@CR17]\]c.1A\>Gp.Met1ValF/6 weeks/6 monthsNo response to GCSFMUD, BM; 9/10(1) Flu--Mel--Cam--ATG (RIC)FkNoRejection/6 monthsRejectionMUD, BM; 9/10(2) Flu--Bu--rATG (MAC)Fk--MTXNRAlive/1 year\[[@CR18]\]\*c.573_597+5 delM/1 year/25 yearsNo response to GCSFMUD, BM;10/10Flu--Cy--ATG--TBICSA--MTXGrade-IV aGVHDDied of aGVHD/128 days*MUD* match unrelated donor, *SIB* sibling donor, *CB* cord blood, *BM* bone marrow, *PBSC* peripheral blood stem cells, *MAC* myeloablative conditioning, *RIC* reduced-intensity conditioning, *Bu* busulfan, *Cy* cyclophosphamide, *ATG* anti-thymoglobulin, *rATG* rabbit ATG, *Flu* fludarabine, *Camp* Campath (alemtuzumab), *Mel* melphalan, *CSA* cyclosporine, *MTX* methotrexate, *Fk* tacrolimus, *Rapa* rapamycin, *Pred* prednisone, *aGVHD* acute graft vs. host disease, *cGVHD* chronic GVHD, *NR* not reported, *MDS--AML* myelodysplasia--acute myeloid leukemia, *TBI* total body irradiation, *RIC* reduced-intensity conditioning, *MAC* myeloablative conditioning.\*Patient carrying the familial Mediterranean fever *MEFV* mutation.

Because our study was an exhaustive examination of a national cohort, with the participation of all French centers, we think that it could be representative of a nonbiased sample of *ELANE-* neutropenia patients. Our first important observation is that the HSCT outcome for *ELANE-* neutropenia patients was good, with overall 95% engraftment survival and 90% long-term survival. Extending HSCT to a small number of patients requiring high-dose GCSF proved beneficial and may lower their risk of AL.

Many data have been collected on *ELANE*-neutropenia patients regarding clonal evolution. The first clonal event was shown to occur in the colony-stimulating factor-3 (*CSF3R*) clone \[[@CR34]\], but the ultimate clonal evolution involved a broader panel of mutations at the time of leukemic transformation \[[@CR35], [@CR36]\]. Although such information is crucial to following patients with *ELANE*-germline mutations, the initial step of leukemogenesis in *ELANE*-neutropenia patients involved *CSF3R* mutations, which appear to be induced by GCSF therapy, and is sufficient to trigger MDS--AL. Taking into consideration the GCSF 'load', key information on early patient management may potentially help make the clinical decision about the HSCT indication.

Our results are limited by the small sample size. Further studies on larger populations could help improve our understanding the GCSF role and what dose can reasonably be considered low risk for leukemic transformation. However, HSCT remains a viable therapeutic option for patients who are difficult to manage and at high risk of severe infections.
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